Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Huntington disease (HD) is described in the packet as a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia. GeneReviews describes it as a progressive disorder with motor, cognitive and psychiatric manifestations. The packet records autosomal dominant inheritance and an uncommon prevalence category of 1 to 9 in 100,000, with a birth prevalence of 3 to 7 per 100,000 people of European descent. Juvenile Huntington disease and Westphal disease are listed as subtypes. The affected organ systems are listed as the nervous system and musculature.
Packet phenotype data list chorea, mental deterioration and hyperreflexia as very frequent features (80-99%). Frequent features (30-79%) include bradykinesia, abnormality of eye movement, gait disturbance and imbalance, dystonia, myoclonus, seizure, clumsiness, generalized muscle weakness, weight loss, memory impairment, apathy, depression, anxiety, irritability, agitation, aggressive behavior, compulsive behaviors, disinhibition, hallucinations and delusion. Characteristic findings in the packet include progressive chorea, cognitive decline and psychiatric symptoms, behavioral changes often preceding motor symptoms, and anticipation, described as earlier onset in successive generations, especially with paternal transmission. GeneReviews describes premanifest stages, presymptomatic and prodromal, followed by manifest disease classed as early, moderate or advanced. It states that individuals with a pathogenic allele are asymptomatic at birth, with no clinical manifestations during childhood and adolescence in the vast majority, and that subtle motor, cognitive or psychiatric changes in the prodromal phase can occur as early as 15 to 20 years before clinical onset.
Huntington disease is caused by a CAG repeat expansion in the HTT gene, located on chromosome 4; ClinGen classifies the gene-disease validity as definitive. The packet states that normal alleles contain fewer than 27 CAG repeats and that alleles with 40 or more repeats are fully penetrant. GeneReviews classifies 26 or fewer repeats as normal, 27 to 35 as intermediate, 36 to 39 as reduced-penetrance and 40 or more as full-penetrance alleles. It states that intermediate alleles are not typically associated with developing HD but, because of germline instability, may be associated with a child having an allele in the HD-causing range, and that asymptomatic individuals with 36 to 39 repeats are common. Inheritance is autosomal dominant. The packet gives a de novo rate of approximately 8% of cases arising through expansion of intermediate alleles, and GeneReviews states that most individuals diagnosed with HD have an affected parent. Paternally inherited intermediate alleles are described as more prone to expansion than maternally inherited ones, and larger repeats as more prone to expansion. GeneReviews also reports that loss of repeat interruptions, found in a minority of alleles, is linked to earlier onset among those with 36 to 39 repeats.
Packet diagnostic methods include molecular genetic testing for CAG repeat length, clinical evaluation of motor, cognitive and psychiatric features, and brain MRI, which may show caudate atrophy. GeneReviews states that HD is suspected with progressive motor disability featuring chorea, cognitive decline and personality or psychiatric changes, with neuroimaging findings of progressive striatal atrophy of the caudate and putamen, enlarged lateral ventricles and gray and white matter atrophy, and a family history consistent with autosomal dominant inheritance, although absence of a known family history does not preclude the diagnosis. It states that the diagnosis is established by a heterozygous CAG trinucleotide repeat expansion in HTT identified by molecular genetic testing. The packet lists neurologists, psychiatrists, genetic counselors, physical therapists, speech-language pathologists and social workers as specialist types. Newborn-screening information is not certified in this packet.
GeneReviews states that there is no cure for HD and that pharmacologic therapy is limited to symptomatic treatment, with supportive care described to improve quality of life and function. Packet foundational therapies include physical therapy for mobility and balance, speech therapy for dysarthria and swallowing difficulties, nutritional support for weight maintenance, and medications for chorea and for depression, anxiety and behavioral symptoms. GeneReviews also lists occupational therapy, psychotherapy and social work support among nonpharmacologic components, and notes that medications for chorea carry significant side effects that can be worse than HD manifestations. Among FDA-approved treatments with ACTIVE market status in the packet are valbenazine (Ingrezza and Ingrezza Sprinkle), deutetrabenazine (Austedo) and tetrabenazine (Xenazine). Orphan-drug records for the disease also include numerous designated products, and a designation is not an approval; withdrawn records are not current options. GeneReviews describes therapies under investigation in human trials, including HTT-lowering RNA-based approaches, gene therapy using AAV vectors, cell replacement and several small molecules, as listed in its pipeline table.
69 trials found
The packet does not certify survival or life expectancy figures. GeneReviews describes HD as progressive, with a mean age of onset of approximately 45 years and onset delayed until after age 50 years in approximately 25% of individuals, some after age 70 years. About two thirds of individuals first present with neurologic manifestations and others with psychiatric changes. In the early stages after diagnosis, GeneReviews states that affected individuals are usually able to perform most daily activities and continue working. It describes progression using the Unified Huntington Disease Rating Scale and total functional capacity, which indicates early, moderate and advanced stages.
Numerous certified active trial records are present on ClinicalTrials.gov. Records in the packet include Phase 3 studies sponsored by Prilenia (NCT07609108, recruiting) and Novartis Pharmaceuticals (NCT07326709, recruiting), a Phase 2 study sponsored by Skyhawk Therapeutics (NCT07378644, recruiting), and Phase 1 studies sponsored by Sarepta Therapeutics (NCT07536061, recruiting), Hoffmann-La Roche (NCT07246941, active, not recruiting) and Vico Therapeutics (NCT05822908, recruiting). Other records are sponsored by Assistance Publique - Hopitaux de Paris, University of Washington, Universidad de Burgos and BioSensics. The packet research directions include HTT-lowering therapies, gene editing approaches and neuroprotective strategies. Trial titles alone do not establish what an intervention involves or whether it is effective.
Data assembled from 10 of 12 sources · Last updated Nov 18, 2026, 8:43 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Huntington disease
AI-curated news mentioning Huntington disease
Updated Nov 17, 2026
At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.
This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.
myositis as a rare forerunner of beh et s disease insights from a new case and review of the literature to unmask a diagnostic trap
liver transplantation as functional gene therapy in wilson s disease a 30 year retrospective single center analysis
stage specific prognosis and treatment outcomes in extramammary paget s disease a retrospective single center study of 104 japanese patients